IOL Chemicals & Pharmaceuticals has announced that it will hold an investor meet in accordance with Regulation 30. The meeting is scheduled for May 29, 2026. The company has not yet released specific details regarding the agenda or the participants who will be in attendance.

Meeting Details

The investor meet is a formal session organized by the company to engage with its investors and provide updates on its business operations. The disclosure was made to ensure compliance with regulatory requirements regarding timely information dissemination.

Regulatory Context

The announcement was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. This regulation mandates listed companies to disclose any material events or information that could influence the decision-making of investors. Further details regarding the specific matters to be discussed are expected to be released in due course.

IOL Chemicals and Pharmaceuticals has reported its audited financial results for the quarter and year ended March 31, 2026. The company recorded a 36.4% year-on-year increase in net profit for the full fiscal year, reaching ₹137.7 crore compared to ₹101.0 crore in the previous year. Revenue from operations for FY26 stood at ₹2,340.3 crore, up from ₹2,101.6 crore in FY25. The EBITDA for the year grew by 29.3% to ₹290.4 crore, with the EBITDA margin improving by 172 basis points to 12.4%.

Q4 Financial Performance

For the quarter ended March 31, 2026, the company demonstrated strong operational efficiency, achieving its highest-ever quarterly revenue. Net profit for Q4 FY26 surged 68.2% to ₹53.2 crore from ₹31.6 crore in the corresponding period of the previous year. Revenue for the quarter increased 17.4% to ₹621.2 crore from ₹532.3 crore in Q4 FY25. EBITDA for the quarter rose 39.8% to ₹94.3 crore, with the EBITDA margin expanding to 15.2% from 12.7%.

Segment Performance

The company's annual results reflected growth across key business segments. The Pharmaceutical segment reported revenue of ₹1,396.3 crore, while the Chemical segment contributed ₹922.8 crore for the year. The Pharmaceuticals segment EBIT increased to ₹172.3 crore from ₹126.3 crore in the previous year. The Chemicals segment also saw improved profitability, with EBIT rising to ₹30.2 crore compared to ₹15.4 crore in FY25.

In Q4 FY26, the Pharmaceutical segment revenue stood at ₹374.5 crore with an EBIT of ₹62.2 crore. The Chemicals segment recorded revenue of ₹244.9 crore and an EBIT of ₹12.8 crore for the same period.

Corporate Developments

The Board of Directors, in its meeting held on May 20, 2026, approved the audited standalone and consolidated financial results. During the year, the company incurred capital expenditure of around ₹164 crore towards capacity expansion and product development. The management highlighted that capacity enhancements in Ethyl Acetate, Acetic Anhydride, and the addition of Triacetin capacity will further strengthen manufacturing capabilities.

Vikas Gupta, Joint Managing Director, noted that the quarter delivered the highest-ever revenue driven by momentum across both businesses. He attributed the profitability growth to a better product mix and operational efficiencies, citing healthy traction in non-Ibuprofen APIs like Paracetamol and Metformin. The company reported a basic and diluted EPS of ₹4.69 for FY26, compared to ₹3.44 in the previous year.